Abstract
Adeno-associated virus (AAV) gene therapy constitutes a powerful tool for the treatment of neurodegenerative diseases. While AAVs are generally administered systemically to newborns in preclinical studies of neurological disorders, in adults the maturity of the blood–brain barrier (BBB) must be considered when selecting the route of administration. Delivery of AAVs into the cerebrospinal fluid (CSF) represents an attractive approach to target the central nervous system (CNS) and bypass the BBB. In this study, we investigated the efficacy of intra-CSF delivery of a single-stranded (ss) AAV9-CAG-GFP vector in adult mice via intracisternal (iCist) or intralumbar (it-Lumb) administration. It-Lumb ssAAV9 delivery resulted in greater diffusion throughout the entire spinal cord and green fluorescent protein (GFP) expression mainly in the cerebellum, cortex and olfactory bulb. By contrast, iCist delivery led to strong GFP expression throughout the entire brain. Comparison of the transduction efficiency of ssAAV9-CAG-GFP versus ssAAV9-SYN1-GFP following it-Lumb administration revealed widespread and specific GFP expression in neurons and motoneurons of the spinal cord and brain when the neuron-specific synapsin 1 (SYN1) promoter was used. Our findings demonstrate that it-Lumb ssAAV9 delivery is a safe and highly efficient means of targeting the CNS in adult mice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Querfurth HW, Laferla FM . Alzheimer’s disease. N Engl J Med 2010; 362: 329–344.
Kalia LV, Lang AE . Parkinson’s disease. Lancet 2015; 386: 896–912.
Renton AE, Chiò A, Traynor BJ . State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014; 17: 17–23.
Faravelli I, Nizzardo M, Comi GP, Corti S . Spinal muscular atrophy—recent therapeutic advances for an old challenge. Nat Rev Neurol 2015; 11: 351–359.
Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N . Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther 2016; 27: 478–496.
Li J, Daly TM . Adeno-associated virus-mediated gene transfer to the neonatal brain. Methods 2002; 28: 203–207.
Taymans J-M, Vandenberghe LH, Van Den Haute C, Thiry I, Deroose CM, Mortelmans L et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 2007; 18: 195–206.
Ciron C, Cressant A, Raoul S, Cherel Y, Hantraye P, De N . Human a—iduronidase gene transfer mediated of nonhuman primates : vector diffusion and biodistribution. Hum Gene Ther 2009; 360: 350–360.
Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59–65.
Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L et al. Original article systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2009; 19: 1971–1980.
Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector–mediated gene transfer in Hemophilia B. N Engl J Med 2011; 365: 2357–2365.
Snyder BR, Gray SJ, Quach ET, Huang JW, Leung CH, Samulski RJ et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther 2011; 1135: 1129–1135.
Samaranch L, Kells AP, Salegio EA, Sebastian WS, Bringas JR, Forsayeth J et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 2013; 532: 526–532.
Bucher T, Dubreil L, Colle M, Maquigneau M, Deniaud J, Ledevin M et al. Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Therapy 2014; 21: 522–528.
Guo Y, Wang D, Qiao T, Yang C . A single injection of recombinant adeno-associated virus into the lumbar cistern delivers transgene expression throughout the whole spinal cord. Mol Neurobiol 2015; 53: 3235–3248.
Hordeaux J, Dubreil L, Deniaud J, Iacobelli F, Moreau S, Ledevin M et al. Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats. Gene Therapy 2015; 22: 316–324.
Vance MA, Mitchell A, Samulski RJ. AAV bology, infectivity and therapeutic use from bench to clinic gene therapy - principles and challenges. Chapter 5, InTech, 2015, pp 119–143.
Jackson KL, Dayton RD, Klein RL . AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats. Mol Ther Methods Clin Dev 2015; 2: 15036.
Tanguy Y, Biferi MG, Besse A, Astord S, Cohen-Tannoudji M, Marais T et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci 2015; 8: 36.
Kilic E, Ba M . Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Therapy 2003; 10: 337–347.
Mclean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ et al. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett 2014; 576: 73–78.
McCarty DM . Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16: 1648–1656.
Dong B, Nakai H, Xiao W . Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010; 18: 87–92.
Wang Y, Ling C, Song L, Wang L, Aslanidi GV, Tan M et al. Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. Hum Gene Ther Methods 2012; 23: 225–233.
Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat 2014; 8: 42.
Lukashchuk V, Lewis KE, Coldicott I, Grierson AJ, Azzouz M . AAV9-mediated central nervous system—targeted gene delivery via cisterna magna route in mice. Mol Ther Methods Clin Dev 2014; 3: 15055.
Samaranch L, Bringas J, Pivirotto P, Sebastian WS, Forsayeth J, Bankiewicz K . Cerebellomedullary cistern delivery for AAV-based gene therapy: a technical note for nonhuman primates. Hum Gene Ther Methods 2016; 27: 13–16.
Gray SJ, Kalburgi SN, Mccown TJ, Samulski RJ . Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Therapy 2013; 20: 450–459.
Dirren E, Aebischer J, Rochat C, Towne C, Schneider BL . SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol 2015; 2: 167–184.
Passini MA, Bu J, Richards AM, Treleaven CM, Sullivan JA, O’Riordan CR et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 2014; 12: 1–12.
Ayers JI, Fromholt S, Sinyavskaya O, Siemienski Z, Rosario AM, Li A et al. Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther 2015; 23: 53–62.
Hinderer C, Bell P, Vite CH, Louboutin J-P, Grant R, Bote E et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev 2014; 1: 14051.
Meyer K, Ferraiuolo L, Schmelzer L, Braun L, Mcgovern V, Likhite S et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA : A Dose–response Study in Mice and nonhuman primates 2015; 23: 477–487.
Timothy R Deer, Jason E Pope. Factors to consider in the choice of intrathecal drug in the treatment of neuropathic pain. Expert Review of Clinical Pharmacology 2015; 8: 507–510.
Shah R, Baqai-stern A, Gulati A . Managing intrathecal drug delivery (ITDD) in cancer patients. Curr Pain Headache Rep 2015; 19: 20.
Samaranch L, San Sebastian W, Kells AP, Salegio EA, Heller G, Bringas JR et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 2014; 22: 329–337.
Sakka L, Coll G, Chazal J . Anatomy and physiology of cerebrospinal fluid. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128: 309–316.
Lim J-A, Li L, Raben N . Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 2014; 6: 177.
Shababi M, Lorson CL, Rudnik-Schöneborn SS . Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat 2014; 224: 15–28.
Lee N, Muramatsu S, Chien Y, Liu W, Wang W, Cheng C et al. Benefits of neuronal preferential systemic gene therapy for neurotransmitter deficiency. Mol Ther 2015; 23: 1572–1581.
Bustos R, Kolen ER, Braiterman L, Baines AJ, Gorelick FS, Hubbard AL . Synapsin I is expressed in epithelial cells : localization to a unique trans-Golgi compartment. J Cell Sci 2001; 114: 3695–3704.
Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I . Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain 2009; 5: 52.
Radford RA, Morsch M, Rayner SL, Cole NJ, Pountney DL, Chung RS . The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci 2015; 9: 414.
Zerah M, Piguet F, Colle M-A, Raoul S, Deschamps J-Y, Deniaud J et al. Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates. Hum Gene Ther Clin Dev 2015; 26: 113–124.
Karumuthil-melethil S, Marshall MS, Heindel C, Jakubauskas B, Bongarzone ER, Gray SJ . Intrathecal administration of AAV/GALC vectors in 10–11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant. J Neurosci Res 2016; 1151: 1138–1151.
Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791–801.
Acknowledgements
This work was supported by a grant from Investissement d'Avenir (ANR-11-INBS-0011—NeurATRIS: A Translational Research Infrastructure for Biotherapies in Neurosciences); the Association Française contre les Myopathies (AFM); and the Région Pays de la Loire.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Gene Therapy website
Rights and permissions
About this article
Cite this article
Bey, K., Ciron, C., Dubreil, L. et al. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther 24, 325–332 (2017). https://doi.org/10.1038/gt.2017.18
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2017.18
This article is cited by
-
Taking the knife to neurodegeneration: a review of surgical gene therapy delivery to the CNS
Acta Neurochirurgica (2024)
-
Ferrostatin-1 facilitated neurological functional rehabilitation of spinal cord injury mice by inhibiting ferroptosis
European Journal of Medical Research (2023)
-
Screening for gene doping transgenes in horses via the use of massively parallel sequencing
Gene Therapy (2022)
-
Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9
Gene Therapy (2022)
-
Treatment of adult metachromatic leukodystrophy model mice using intrathecal administration of type 9 AAV vector encoding arylsulfatase A
Scientific Reports (2021)